Shankar Siva

Sep 20, 2024 | europeanurology.com | David Chen |Alice Thomson |Elio Mazzone |Marlon Perera |Nathan Lawrentschuk |Shankar Siva | +1 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia bDepartment of Urology, Austin Hospital, Heidelberg, Australia cSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia dDepartment of Urology,...

Apr 11, 2024 | urotoday.com | Shankar Siva

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Dr. Shankar Siva, who is joining me from Melbourne at the Peter Mac, where he's a professor of radiation oncology. Thank you so much for being here with me today. Shankar Siva: Thank you very much for having me. Very excited to talk to you. Alicia Morgans: Wonderful.

Mar 30, 2023 | redjournal.org | Nicholas G Zaorsky |Alexander Louie |Shankar Siva

IntroductionStereotactic body radiation therapy is a treatment option for treatment of primary and metastatic renal cell carcinoma, and it can be used in lieu of systemic therapy or combined with certain systemic therapies. 1Ali M Mooi J Lawrentschuk N et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol.

Jan 22, 2023 | jamanetwork.com | Shankar Siva |Muhammad Ali

[Skip to Navigation] January 12, 2023 JAMA Oncol. Published online January 12, 2023. doi:10.1001/jamaoncol.2022.6334 Full Text Improving the accuracy of radiotherapy delivery is a fundamental goal of the radiation oncology community.